124 related articles for article (PubMed ID: 11780581)
1. Plasma and mucosal prostaglandin E2 as a surrogate marker of ulcerative colitis activity.
Wiercińska-Drapało A; Flisiak R; Prokopowicz D
Rocz Akad Med Bialymst; 2001; 46():60-8. PubMed ID: 11780581
[TBL] [Abstract][Full Text] [Related]
2. Mucosal and plasma prostaglandin E2 in ulcerative colitis.
Wiercinska-Drapalo A; Flisiak R; Prokopowicz D
Hepatogastroenterology; 1999; 46(28):2338-42. PubMed ID: 10521993
[TBL] [Abstract][Full Text] [Related]
3. Effects of ulcerative colitis activity on plasma and mucosal prostaglandin E2 concentration.
Wiercińska-Drapało A; Flisiak R; Prokopowicz D
Prostaglandins Other Lipid Mediat; 1999 Oct; 58(2-4):159-65. PubMed ID: 10560618
[TBL] [Abstract][Full Text] [Related]
4. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis.
Raab Y; Sundberg C; Hällgren R; Knutson L; Gerdin B
Am J Gastroenterol; 1995 Apr; 90(4):614-20. PubMed ID: 7717321
[TBL] [Abstract][Full Text] [Related]
5. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1.
Wiercińska-Drapało A; Flisiak R; Prokopowicz D
Cytokine; 2001 Jun; 14(6):343-6. PubMed ID: 11497495
[TBL] [Abstract][Full Text] [Related]
6. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis.
Renzi D; Mantellini P; Calabrò A; Panerai C; Amorosi A; Paladini I; Salvadori G; Garcea MR; Surrenti C
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):62-70. PubMed ID: 9615269
[TBL] [Abstract][Full Text] [Related]
7. Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients.
Lok KH; Ng CH; Hung HG; Li KF; Li KK; Szeto ML
J Dig Dis; 2008 Nov; 9(4):219-24. PubMed ID: 18959594
[TBL] [Abstract][Full Text] [Related]
8. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients.
Wiercinska-Drapalo A; Jaroszewicz J; Tarasow E; Flisiak R; Prokopowicz D
Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):160-8. PubMed ID: 16303613
[TBL] [Abstract][Full Text] [Related]
10. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Vassiliadis T; Mpoumponaris A; Giouleme O; Evgenidis N
Med Sci Monit; 2009 Nov; 15(11):CR563-72. PubMed ID: 19865055
[TBL] [Abstract][Full Text] [Related]
11. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis.
Osada T; Ohkusa T; Okayasu I; Yoshida T; Hirai S; Beppu K; Shibuya T; Sakamoto N; Kobayashi O; Nagahara A; Terai T; Watanabe S
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S262-7. PubMed ID: 19120909
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
Griga T; May B; Pfisterer O; Müller KM; Brasch F
Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal/permeability-increasing protein in colonic mucosa in ulcerative colitis.
Haapamäki MM; Häggblom JO; Grönroos JM; Pekkala E; Alanen K; Nevalainen TJ
Hepatogastroenterology; 1999; 46(28):2273-7. PubMed ID: 10521980
[TBL] [Abstract][Full Text] [Related]
15. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis.
Mawdsley JE; Macey MG; Feakins RM; Langmead L; Rampton DS
Gastroenterology; 2006 Aug; 131(2):410-9. PubMed ID: 16890594
[TBL] [Abstract][Full Text] [Related]
16. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis.
Mawdsley JE; Jenkins DG; Macey MG; Langmead L; Rampton DS
Am J Gastroenterol; 2008 Jun; 103(6):1460-9. PubMed ID: 18510607
[TBL] [Abstract][Full Text] [Related]
17. Direct determination of colonic nitric oxide level--a sensitive marker of disease activity in ulcerative colitis.
Rachmilewitz D; Eliakim R; Ackerman Z; Karmeli F
Am J Gastroenterol; 1998 Mar; 93(3):409-12. PubMed ID: 9517649
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-elastase in chronic inflammatory bowel disease: a marker of disease activity?
Gouni-Berthold I; Baumeister B; Wegel E; Berthold HK; Vetter H; Schmidt C
Hepatogastroenterology; 1999; 46(28):2315-20. PubMed ID: 10521989
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis.
Alagozlu H; Gorgul A; Bilgihan A; Tuncer C; Unal S
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):80-5. PubMed ID: 22572519
[TBL] [Abstract][Full Text] [Related]
20. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.
Sharon P; Ligumsky M; Rachmilewitz D; Zor U
Gastroenterology; 1978 Oct; 75(4):638-40. PubMed ID: 30669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
